Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacopoeia 2010 Edition To Be Ready Mid 2010

This article was originally published in PharmAsia News

Executive Summary

According to the Chinese Pharmacopoeia Commission, Chinese Pharmacopoeia 2010 edition is scheduled to be finalized in late August (PharmAsia News, Dec. 15, 2008). China Medico-Pharmaceutical Science & Technology Publishing House will start publishing and distributing the publication beginning in 2010, with the new standards taking effect July 1. Some major changes have been made in the explanatory notes, standards requirements, general principles of formulation and testing methodologies, with expanded appendices and an increased list of medicines. To ensure drug safety, the revision puts more emphasis on drug safety and quality controllability, adding more controlling index and testing methods. Specialized identification techniques are also included that cater to TCM's characteristics. (Click here for more - Chinese language)

You may also be interested in...



Revised Pharmacopoeia 2010 Edition Focuses On Standardization

The 9th Chinese Pharmacopoeia Commission, established in 2007, recently held a working meeting to discuss the revision of Chinese Pharmacopoeia 2010 edition (PharmAsia News, Feb. 4, 2008). The new directory will focus on raising the standards of TCM, biochemical drugs and injections. The revision will modify those drugs with weak standards or whose methodology cannot be duplicated, as well as eliminate drugs which are not applicable in clinical practice or which have quality control or potential safety risks. A separate injection drug commission will be in charge of collecting injection data and understanding existing problems based on specific subjects such as TCM, antibiotics and biological products. The commission hopes that suggestions contributed will help conceptualize a basic platform for the field. (Click here for more - Chinese Language)

Roche’s Tecentriq Gets Another Indication In India But Pricing Hurts

Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.

QUOTED. 11 December 2019. Tejas Patel.

Corindus Vascular Robotics Inc. expects its CorPath GRX robotic intervention system will eventually be part of a widespread system of "telerobotic" intervention sites operated by specialists located far away. See what Tejas Patel, an interventional cardiologist at the Apex Heart Institute in Ahmedabad, India, said about it here.

UsernamePublicRestriction

Register

SC072310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel